A425 as a first-line therapy for VAP. Clinical Cure, utilization data, incidence of adverse events, days on mechanical ventilation (MV), ICU days, and LOS in hospital, were estimated by combining data from two randomized multicenters, non-inferiority clinical trials of doripenem. Only direct medical costs were considered. Unitary costs of MV, ICU, ward days and drugs costs were obtained from the IMSS. The primary outcomes were total costs and incremental cost per clinical cure. Sensitivity analyses included one-way scenarios and probabilistic analyses (SPA). Results are shown in percents, while costs are expressed in Dollars. RESULTS: Doripenem was the least expensive treatment in patients with VAP, and in average generated savings of $3,374.47/treated patient vs imipenem and $985.04/treated patient vs PT. Doripenem dominated PT by being less costly with better clinical cure (72.3% vs 67.8%) Imipenem had a clinical cure rate of 72.6% , but an additional cost of $229,152.1/cure. Median hospital LOS and mechanical ventilation were significantly shorter with doripenem than imipenem (22 vs 27 days; P 0.010 and 7 vs 10 days; P 0.034). One-way sensitivity analysis shows that the model is sensitive unitary cost of ICU and MV days and clinical cure. The probabilities to be cost-saving are Doripenem 90.1% versus Imipenem and 98% versus PT of 1,000 iterations in SPA. CONCLUSIONS: The utilization of Doripenem as a first-line therapy in adult patients with VAP is a cost-effective health intervention and results in considerable savings, compared with imipenem and piperazilina-tazobactam due to a significantly reduced LOS in the ICU units.
as a first-line therapy for VAP. Clinical Cure, utilization data, incidence of adverse events, days on mechanical ventilation (MV), ICU days, and LOS in hospital, were estimated by combining data from two randomized multicenters, non-inferiority clinical trials of doripenem. Only direct medical costs were considered. Unitary costs of MV, ICU, ward days and drugs costs were obtained from the IMSS. The primary outcomes were total costs and incremental cost per clinical cure. Sensitivity analyses included one-way scenarios and probabilistic analyses (SPA) . Results are shown in percents, while costs are expressed in Dollars. RESULTS: Doripenem was the least expensive treatment in patients with VAP, and in average generated savings of $3,374.47/treated patient vs imipenem and $985.04/treated patient vs PT. Doripenem dominated PT by being less costly with better clinical cure (72.3% vs 67.8%) Imipenem had a clinical cure rate of 72.6% , but an additional cost of $229,152.1/cure. Median hospital LOS and mechanical ventilation were significantly shorter with doripenem than imipenem (22 vs 27 days; P 0.010 and 7 vs 10 days; P 0.034). One-way sensitivity analysis shows that the model is sensitive unitary cost of ICU and MV days and clinical cure. The probabilities to be cost-saving are Doripenem 90.1% versus Imipenem and 98% versus PT of 1,000 iterations in SPA. CONCLUSIONS: The utilization of Doripenem as a first-line therapy in adult patients with VAP is a cost-effective health intervention and results in considerable savings, compared with imipenem and piperazilina-tazobactam due to a significantly reduced LOS in the ICU units. To determine the most cost-effective alternative for influenza prevention in Mexican elderly population in a pandemic case scenario. METHODS: A costeffectiveness study was performed with Mexican Public Health Institution perspective comparing the use of MF59-adjuvanted vaccine (MF59), split vaccine (SPL) and a No Vaccination Program Alternative (NOVA). A systematic review of literature was designed in order to evaluate the effectiveness of MF59 and SPL measured as hemagglutination-inhibition antibody titers against A/H1N1 strain, and to calculate the influenza incidence in a pandemic case scenario. A cost matrix was calculated considering vaccines, vaccination program, medical visits, influenza and influenza related complications treatment, hospitalization and intensive care unit cost. Different proportions of patients with influenza were considered to determine complications related to the disease. Use of resources for complication treatment was assumed to be the same for every alternative evaluated. A decision tree was designed to simulate the use of resources. Results were evaluated with incremental analysis and sensitivity analysis of the most uncertain variables (influenza incidence, vaccine effectiveness, percentage of patients developing complications related to influenza) in order to establish robustness of the study. RESULTS: The use of MF59 represents the lowest cost per patient avoiding influenza or complications related to influenza when compared with the use of SPL or NOVA (MF59: US$25.17; SPL: US$40.50; NOVA: US$127.27) due to reduced institutional expenses. The ICER shows that MF59 is a dominant alternative in prevention of influenza and its complications while the sensitivity analysis exhibits robustness for the base study. CONCLUSIONS: MF59 is the most cost-effective alternative in influenza prevention for elderly population when a pandemic case scenario in Mexico is simulated. The use of MF59 represents savings estimated in US$15.32 and US$102.10 per patient avoiding influenza when compared to SPL and NOVA, respectively. This was expanded to all children under the age of two in 2006. In 2009 higher valent pneumococcal conjugate vaccines (PCV) will enter the German market. Aim of this study is to evaluate cost-effectiveness ratios in children compared to the current standard immunization (PCV7) in Germany. METHODS: A markov model compares in a steady state the historical epidemiological situation (without vaccination) with existing and upcoming PCV. For all vaccines incidence and cost of pneumococcal infections for children (meningitis; bacteraemia; pneumonia and AOM) is considered. Additionally herd immunity effects for adults based on published data are included. In the base case the underlying vaccination regime was 3 1 with a vaccine uptake of 90%. RESULTS: In the base case PCV7, PCV10 and PCV13 reduce IPD cases on a population level by 4593, 5305, and 6092, respectively. If herd immunity in the unvaccinated population is considered, all three PCV are cost-saving. A general vaccination with PCV13 dominates the 10-and 7-valent PCV. The validated effect of PCV on nasopharyngeal carriage results in herd immunity in non-vaccinated populations. Depending on vaccine uptake, this effect helps PCV13 to prevent costs of a1.40 (90% uptake) and a1.70 (80% uptake) for every Euro spent on vaccination. In sensitivity analyses the results were robust to variation of input variables. CONCLUSIONS: Compared to other existing PCV, PCV13 is a dominant cost-effective option to prevent pneumococcal diseases. Not only from a medical and epidemiological point of view, but also from a health-economic perspective an immediate change from PCV7 to PCV13 should be considered.
PIN41

PREVENTION OF AN INFLUENZA PANDEMIC IN MEXICO: ESTABLISHING A COST-EFFECTIVE ALTERNATIVE FOR ELDERLY POPULATION
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COST-EFFECTIVENESS OF SWITCHING STRATEGIES FROM A 7-VALENT TO A 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
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COST-EFFECTIVENESS OF 13-VALENT AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION RELATIVE TO 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION IN CANADA
Whillans F 1 , Kwan H 1 , Strutton DR 2 , Earnshaw SR 3 , Farkouh R 3 1 Wyeth Pharmaceuticals, Markham, ON, Canada, 2 Wyeth Research, Collegeville, PA, USA, 3 RTI Health Solutions, Research Triangle Park, NC, USA OBJECTIVES: Seven-valent pneumococcal conjugate vaccine (PCV7) has demonstrated dramatic public health impact and is considered highly cost-effective. Introduction of two new pneumococcal conjugate vaccines, 10-valent (PCV10) which is conjugated to protein-D, tetanus and diphtheria toxoids and 13-valent (PCV13) which is conjugated to CRM197 similar to PCV7, provides coverage to an additional 3 and 6 serotypes respectively, which is likely to result in further reduction in pneumococcal disease. We examined the incremental public health impact and cost-effectiveness of two new vaccines compared to PCV7 in Canada. METHODS: A decision-analytic model (payer perspective) was developed to estimate impact of PCV13 and PCV10 vs. PCV7 on invasive pneumococcal disease (IPD), pneumonia, and acute otitis media (AOM). We used an epidemiological approach to track serotype specific incidence, disease sequelae, death, and costs. Incidence, disease sequelae, indirect effects, utilities, and mortality data were obtained from surveillance systems in the province of Alberta, national vital statistics and published literature. Direct effects for PCV13 serotypes were assumed similar to those for PCV7 serotypes, whereas PCV10 was assumed to be less effective due to lower immunogenicity for the seven common serotypes. A 4dose schedule and parity pricing were assumed. RESULTS: When indirect effects due to herd immunity were considered for PCV7, PCV7 resulted in less costs and greater benefits than PCV10. In the absence of indirect effects, the ICER for PCV10 vs. PCV7 was $771,938 per QALY. PCV13 was cost saving compared to PCV7, whether indirect effects or direct effects alone were considered. Through direct effects, PCV13 pediatric vaccination would reduce 60% of IPD in vaccinated children. CONCLU-SIONS: PCV7 is estimated to be cost saving compared to PCV10. The broader serotype coverage of PCV13 would provide additional protection against pneumococcal disease and PCV13 is expected to be cost saving.
PIN44 A COST-EFFECTIVENESS ANALYSIS OF MICAFUNGIN VERSUS CASPOFUNGIN FOR TREATMENT OF SYSTEMIC CANDIDA INFECTIONS IN ITALY
Sidhu MK 1 , Van Engen AK 2 , Switjnk AB 2 , Concia E 3 1 Astellas Pharma Europe Ltd, Staines, UK, 2 Quintiles Consulting, Hoofddorp, The Netherlands, 3 University of Verona, Verona, Italy OBJECTIVES: To evaluate the cost-effectiveness of micafungin compared to caspofungin in the treatment of systemic Candida infections (SCIs) in Italy, including invasive candidiasis and candidaemia. METHODS: Cost-effectiveness of both echinocandin antifungal drugs was estimated using decision analysis. Response to treatment, resource utilisation, and costs in the model were derived from a phase 3, head-to-head comparative trial. The model includes only data directly related to the treatment of the systemic Candida infection over the study duration (a maximum period of 14 weeks). Transition probabilities were calculated based on the efficacy results from the clinical trial. The model's effectiveness outcome is surviving patients who are successfully treated, based on the absence of signs and symptoms, radiographic abnormalities, and culture/histologic evidence associated with the fungal infection. In addition, subgroup analyses were performed to identify cost-effectiveness in several specific patient groups. RESULTS: The total medical treatment costs for the micafungin group were a30,758 , which is similar to the total costs for the caspofungin group (a31,923). In the micafungin arm 60% of the patients and in the caspofungin arm 58% of the patients were successfully treated and alive. Cost-effectiveness ratio of micafungin was a51,558, and of caspofungin a55,489 per successfully treated patient. Because the costs are lower and the effectiveness is higher for micafungin in comparison with caspofungin, micafungin is more cost-effective than caspofungin. Probabilistic sensitivity and subgroup analysis show that although the difference cannot be considered significant, due to a large variance, micafungin was the most cost-effective option in all subgroup analyses except one. CONCLUSIONS: Costs and effects of micafungin compare favourably to those of caspofungin in the treatment of systemic Candida infections in Italy. Sensitivity analysis showed that despite the uncertainty in costeffectiveness ratio this result is robust. Subgroup analyses showed similar results.
